希罗达治疗晚期癌症临床观察

Clinical observation on treatment of advanced cancer with Xeloda

目的观察希罗达对晚期大肠癌和乳腺癌的疗效和安全性。方法采用希罗达治疗21例晚期大肠癌或乳腺癌患者,希罗达剂量为2500mg/m2,每天分两次口服,连服两周休息一周为一周期,至少化疗两周期后评价疗效,CR+PR为有效。结果21例患者全部可评价疗效,其中CR1例,PR4例,总有效率(CR+PR)为23.8%。患者中位疾病进展时间为6.5个月。主要毒性作用为手足综合征,其他有恶心呕吐、皮肤色素沉着、腹泻。结论希罗达对晚期大肠癌和乳腺癌疗效高,安全性好。

Objective To observe the efficacy and safety of Xeloda in treatment of advanced colorectal cancer and advanced breast cancer.Methods Twenty-one cases of advanced colorectal cancer or breast cancer received Xeloda, which was administered twice daily from day 1 to 14 and recycled every 21 days for at least two cycles. The dose of Xeloda was 2500 mg/m^2.The response and toxicity of chemotherapy was assessed according to the WHO criteria.Results The overall response rate was 23.8%.The complete response and partial response were (4.8%) and 19.0% respectively.Foot-hand syndrome was the main adverse effect in all treated cases.Other adverse effects were nausea/vomiting, skin pigmentation and diarrhea.Mean time to progression (TTP) of all the patients was 6.5 months.Conclusion A high response rate was obtained in advanced malignant colorectal cancer and breast cancer treated with Xeloda.